H5166
Erythropoietin 人
EPO, recombinant, expressed in HEK 293 cells, suitable for cell culture
别名:
EPO
生物来源
human
质量水平
重组
expressed in HEK 293 cells
方案
≥95% (SDS-PAGE)
表单
lyophilized powder
效能
≤5.0 ng/mL ED50
质量
endotoxin tested
分子量
dimer 36 kDa (glycosylated)
包装
pkg of 10 μg
储存条件
avoid repeated freeze/thaw cycles
技术
cell culture | mammalian: suitable
杂质
≤1 EU/μg
UniProt登记号
储存温度
−20°C
基因信息
human ... EPO(2056)
正在寻找类似产品? 访问 产品对比指南
一般描述
EPO has been cloned from various species including human, murine, canine, and others. The mature proteins from the various species are highly conserved and exhibit greater than 80% amino acid sequence identity. EPO contains three N-linked glycosylation sites. The glycosylation of erythropoietin is required for the biological activities of erythropoietin in vivo.
生化/生理作用
Erythropoietin is a glycoprotein that is the principal regulator of red blood cell growth and differentiation.
Erythropoietin (EPO), produced primarily by the kidney, is the primary regulatory factor of erythropoiesis. It promotes the proliferation, differentiation, and survival of the erythroid progenitors. Erythropoietin stimulates erythropoiesis by inducing growth and differentiation of burst forming units and colony forming units into mature red blood cells. EPO produced by kidney cells is increased in response to hypoxia or anemia. The biological effects of erythropoietin are mediated by the erythropoietin receptor, which binds EPO with high affinity and is a potent EPO antagonist.
制备说明
Human EPO is expressed as a glycosylated 36 kDa monomer in human HEK 293 cells. Production in human HEK 293 cells offers authentic glycosylation. Glycosylation contributes to stability in cell growth media and other applications.
分析说明
The specific activity was determined by the dose-dependent stimulation of the proliferation of human TF-1 cells (human erythroleukemic indicator cell line).
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
胰岛素激素类产品
常规特殊物品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Rajasekhar N V S Suragani et al.
Nature medicine, 20(4), 408-414 (2014-03-25)
Erythropoietin (EPO) stimulates proliferation of early-stage erythrocyte precursors and is widely used for the treatment of chronic anemia. However, several types of EPO-resistant anemia are characterized by defects in late-stage erythropoiesis, which is EPO independent. Here we investigated regulation of
Claudia S Robertson et al.
JAMA, 312(1), 36-47 (2014-07-25)
There is limited information about the effect of erythropoietin or a high hemoglobin transfusion threshold after a traumatic brain injury. To compare the effects of erythropoietin and 2 hemoglobin transfusion thresholds (7 and 10 g/dL) on neurological recovery after traumatic
Cynthia So-Osman et al.
Anesthesiology, 120(4), 839-851 (2014-01-16)
Patient blood management combines the use of several transfusion alternatives. Integrated use of erythropoietin, cell saver, and/or postoperative drain reinfusion devices on allogeneic erythrocyte use was evaluated using a restrictive transfusion threshold. In a factorial design, adult elective hip- and
H Franklin Bunn
Cold Spring Harbor perspectives in medicine, 3(3), a011619-a011619 (2013-03-05)
During the past century, few proteins have matched erythropoietin (Epo) in capturing the imagination of physiologists, molecular biologists, and, more recently, physicians and patients. Its appeal rests on its commanding role as the premier erythroid cytokine, the elegant mechanism underlying
Russia Ha-Vinh Leuchter et al.
JAMA, 312(8), 817-824 (2014-08-27)
Premature infants are at risk of developing encephalopathy of prematurity, which is associated with long-term neurodevelopmental delay. Erythropoietin was shown to be neuroprotective in experimental and retrospective clinical studies. To determine if there is an association between early high-dose recombinant
商品
Discover validated bioactivity and proliferation data for our portfolio of animal component-free cell culture growth factors.
Read article on hematopoietic cytokines and hematopoiesis
实验方案
Stem cell reprogramming protocols to generate human induced pluripotent stem cells (iPSCs) including viral and non-viral RNA based methods.
产生人诱导多能干细胞（iPSC）的干细胞重编程实验方案，包括基于病毒和非病毒RNA的方法。
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持